Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc. operates as a commercial-stage biotechnology company with a primary focus in oncology market. The company focuses on acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products. Its marketed products include ZEVALIN, a form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma; and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. The company also develops apaziquone for the treatment of non-muscle invasive bladder cancer. Its phase II products comprise Ozarelix, a drug being investigated for benign prostatic hypertrophy, a non-cancerous enlargement of the prostate; and Ortataxel, a third-generation taxane. In addition, Spectrum Pharmaceuticals, Inc. has exclusive worldwide rights to Renazorb, Renalan, and related compounds. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.

Contact Details

Office Address

Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine, CA, USA 92618
Phone: (949) 788-6700
Fax: (949) 788-6706

Executives

Chairman & Chief Exec. Officer

Dr. Rajesh C. Shrotriya

Principal Financial Officer

Mr. Shyam K. Kumaria

Business Reviews for Spectrum Pharmaceuticals, Inc.

Related Companies